Evidence map›Paper›PMID 40813540›Full record

ArticleApoptosis : an international journal on programmed cell death2025

FOXP2/SOS1/AKT negative feedback loop inhibits cell proliferation in KRAS-mutant colorectal cancer.

Jinpu Liu, Yayun Wang, Yuya Liu, Hanwei Mei, Qiaonan Zhang, Zhanhua Gao, Miao Zhang, Zhen Yang, Huaqing Wang, Minghan Qiu

Abstract read
PubMed Publisher
In one paragraph

Article in Apoptosis : an international journal on programmed cell death, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Jinpu Liu *Department of Oncology, Tianjin Union Medical Center, The First Affiliated Hospital of Nankai University, Tianjin, 300121, China.
Yayun Wang *Department of Oncology, Tianjin Union Medical Center, The First Affiliated Hospital of Nankai University, Tianjin, 300121, China.
Yuya Liu *Department of Thyroid and Breast Surgery, Tianjin Union Medical Center, The First Affiliated Hospital of Nankai University, Tianjin, 300121, China.
Hanwei MeiDepartment of Gastrointestinal Surgery 3, Tianjin Nankai Hospital, Tianjin Medical University, Tianjin, 301617, China.
Qiaonan ZhangSchool of Medicine, Nankai University, Tianjin, 300071, China.
Zhanhua GaoSchool of Medicine, Nankai University, Tianjin, 300071, China.
Miao ZhangDepartment of Oncology, Tianjin Union Medical Center, The First Affiliated Hospital of Nankai University, Tianjin, 300121, China. Zhangmiao810208@126.com.
Zhen YangTianjin Cancer Institute of Integrative Traditional Chinese and Western Medicine, Tianjin Union Medical Center, The First Affiliated Hospital of Nankai University, Tianjin, 300121, China. yangz_tumc@126.com.
Huaqing WangDepartment of Oncology, Tianjin Union Medical Center, The First Affiliated Hospital of Nankai University, Tianjin, 300121, China. huaqingw@163.com.
Minghan QiuDepartment of Oncology, Tianjin Union Medical Center, The First Affiliated Hospital of Nankai University, Tianjin, 300121, China. qiuminghan@163.com.

Funding

Institutional Project of Tianjin Union Medical Center 2019YJ006Tianjin Key Medical Discipline (Specialty) TJYXZDXK-053BTianjin Key Specialty Construction Project for combining traditional Chinese and Western medicine ZDZKKF02
6 · The paper itself

Abstract

FOXP2, a member of the Forkhead box transcription factor family, has been implicated in diverse biological processes and malignancies. However, its role in colorectal cancer (CRC), particularly in the context of KRAS mutations, remains poorly defined. Here, we analyzed FOXP2 expression in CRC datasets and clinical specimens, and conducted functional assays-including colony formation, cell viability, EdU incorporation, and cell cycle analysis-in KRAS-mutant CRC cell lines with FOXP2 overexpression or knockdown. Western blotting, dual-luciferase reporter assays, and in vivo xenograft models were used to explore the underlying mechanisms. FOXP2 was significantly downregulated in CRC tissues and its high expression correlated with favorable prognosis in KRAS-mutant patients. Functionally, FOXP2 overexpression suppressed cell proliferation, induced G0/G1-phase arrest, and inhibited PI3K/AKT signaling. Mechanistically, FOXP2 transcriptionally repressed SOS1, thereby attenuating downstream AKT activation. Notably, AKT activation enhanced FOXP2 expression, indicating a FOXP2/SOS1/AKT negative feedback loop. Collectively, our findings suggest that FOXP2 inhibits proliferation in KRAS-mutant CRC by suppressing SOS1-mediated PI3K/AKT signaling, and may serve as a prognostic biomarker and potential therapeutic target in KRAS-driven CRC.

Indexed as

Colorectal NeoplasmsForkhead Transcription FactorsProto-Oncogene Proteins c-aktProto-Oncogene Proteins p21(ras)Repressor ProteinsSOS1 ProteinAnimalsCell Line, TumorCell ProliferationFeedback, PhysiologicalFemaleGene Expression Regulation, NeoplasticHumansMaleMiceMice, Inbred BALB CForkhead Transcription FactorsFOXP2 protein, humanKRAS protein, humanPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktProto-Oncogene Proteins p21(ras)Repressor ProteinsSOS1 ProteinSOS1 protein, humanColorectal cancerFOXP2KRASPI3K/AKT signalingSOS1

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.